Related Experiment Video
Updated: Feb 21, 2026
Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel
Published on: September 8, 2017
DKK4-knockdown enhances chemosensitivity of A549/DTX cells to docetaxel
Xueliang Yang1,2, Yang Liu1, Weina Li3
1Department of Thoracic Surgery, General Hospital of Chinese PLA, Beijing 100853, China.
Abstract:
Drug resistance greatly limits docetaxel efficiency in the treatment of non-small cell lung cancer (NSCLC). Dickkopf 4 (DKK4), a negative regulator of Wnt/β-catenin pathway, is believed to be involved in various human cancers; whereas the association of DKK4 with acquired docetaxel resistance in NSCLC remains unclear. In the present study, we investigated the involvement of DKK4 in the docetaxel-resistant human lung adenocarcinoma A549 (A549/DTX) cells. Our results showed that DKK4 expression was significantly increased in the A549/DTX cells compared with in the A549 cells, as well as in the culture supernatant of A549/DTX cells. DKK4 overexpression increased the resistance of A549 cells to docetaxel. DKK4-knockdown promoted inhibition of A549/DTX cell growth, and reduced the colony formation and invasion capacity of A549/DTX cells. Moreover, DKK4-knockdown promoted the pro-apoptotic effect of docetaxel characterized with caspase 3 activation and inhibition of BCL-2 expression in A549/DTX cells, which was possibly mediated by inducing the activation of c-Jun N-terminal kinase (JNK)-related signaling pathway. Thus, our results indicated that DKK4-knockdown promoted the cytotoxic and pro-apoptotic activity of A549/DTX cells, which suggests a critical role of DKK4 in docetaxel resistance of the A549 cells and provides the potential to combine docetaxel therapy with DKK4 depletion in treating NSCLC.
Insights
Dickkopf 4 (DKK4) is elevated in docetaxel-resistant non-small cell lung cancer (NSCLC) cells. Reducing DKK4 enhances docetaxel
Area of Science:
- Oncology
- Molecular Biology
- Cancer Research
Background:
- Drug resistance, particularly to docetaxel, significantly impedes effective treatment for non-small cell lung cancer (NSCLC).
- Dickkopf 4 (DKK4), a Wnt/β-catenin pathway inhibitor, is implicated in various cancers, but its role in acquired docetaxel resistance in NSCLC is not well understood.
Purpose of the Study:
- To investigate the role of DKK4 in the development of docetaxel resistance in human lung adenocarcinoma A549 cells.
- To explore the therapeutic potential of targeting DKK4 in overcoming docetaxel resistance in NSCLC.
Main Methods:
- Comparative analysis of DKK4 expression in docetaxel-sensitive (A549) and docetaxel-resistant (A549/DTX) human lung cancer cells.
- Assessment of DKK4's impact on docetaxel sensitivity, cell growth, colony formation, and invasion.
- Evaluation of DKK4-knockdown effects on apoptosis, caspase 3 activation, BCL-2 expression, and the JNK signaling pathway.
Main Results:
- DKK4 expression was significantly upregulated in A549/DTX cells and their culture supernatant compared to A549 cells.
- DKK4 overexpression conferred docetaxel resistance, while DKK4 knockdown sensitized A549/DTX cells to docetaxel.
- DKK4 knockdown inhibited A549/DTX cell proliferation, colony formation, and invasion, while promoting docetaxel-induced apoptosis via caspase 3 activation and BCL-2 inhibition, potentially through JNK pathway activation.
Conclusions:
- DKK4 plays a critical role in mediating docetaxel resistance in A549 lung cancer cells.
- Targeting DKK4 through knockdown enhances the cytotoxic and pro-apoptotic effects of docetaxel.
- DKK4 depletion presents a potential therapeutic strategy for combination therapy to improve docetaxel efficacy in NSCLC treatment.
More Related Videos
06:02Live Imaging to Study Microtubule Dynamic Instability in Taxane-resistant Breast Cancers
Published on: February 20, 2017
13:54Preparation of Cell-lines for Conditional Knockdown of Gene Expression and Measurement of the Knockdown Effects on E4orf4-Induced Cell Death
Published on: October 21, 2012